A nationwide Danish cohort study reports cardiovascular events up to 1 year after infection, comparable to that observed with influenza. A nationwide Danish cohort study reports cardiovascular events ...

A new study by the University of Oxford, published in the journal npj Vaccines, shows that a vaccine against respiratory syncytial virus (RSV) is associated with a 29% reduction in dementia risk in ...

DEAR DR. ROACH: A cardiologist recently suggested that I should consider taking a statin because of my “borderline” cholesterol level. So, I took a dive into the details of statin therapy. I learned ...

Respiratory syncytial virus (RSV) has been a continuous and major cause of morbidity and mortality in babies and older people ...

Yes, adults can get RSV (respiratory syncytial virus). In fact, most adults have had an RSV infection at least once in their lives. This seasonal virus is so widespread that almost all of us have had ...

Changes in the vaccine advisory process in the United States have disrupted immunization guidance, which reinforces the need for independent evidence review to inform decisions regarding immunization ...

Dual long‑acting antibodies that lock RSV’s fusion protein from two sides protect against RSV A and B and prevent resistance, ...

Among allogeneic hematopoietic cell transplant recipients, the use of sirolimus for graft-vs-host disease (GVHD) prophylaxis was linked to a higher risk for respiratory syncytial virus (RSV) infection ...

What Is Arexvy, and Why Does It Matter? Arexvy is a vaccine that helps protect against serious lung illness caused by respiratory syncytial virus (RSV). The FDA has expanded its use to include people ...